Theralase(TM) Technologies Inc. Closes Private Placement



    TORONTO, Aug. 16 /CNW/ - Theralase(TM) Technologies Inc. (TSX-V: TLT &
OTC BB: TLTFF) announces that it has closed its previously announced private
placement which raised gross proceeds of $850,000 by issuing 1,700,000 units
to investors at a price of $0.50 per unit. Each unit consists of 1 common
share and 1/2 of a non-transferable common share purchase warrant. Each whole
warrant entitles the holder thereof to purchase 1 additional common share at a
price $0.75, until August 15th, 2008. All common shares sold under this
private placement, including shares issuable upon the exercise of the
warrants, are restricted from trading until December 16th, 2007. Two
registered dealers were paid cash commissions totalling $25,550 in connection
with the private placement.

    Roger White, President and CEO of Theralase Technologies Inc. stated
that, "This is an important development for the Company, allowing us to
accelerate our growth in our three main strategic initiatives:

    
    1)  US sales and marketing of the TLC-1000 biomedical laser technology.
    2)  Commercialization of the patented TLC-2000 biofeedback biomedical
        laser technology able to precisely target tissue at depth with a
        known dose of energy representing a huge advancement in the
        technology.
    3)  Research and development of the TLC-3000 biomedical laser technology
        combined with our patented photodynamic compounds, that if proven
        successful would be able to selectively destroy cancers, bacterium,
        viruses and even fat cells.
    

    The Company feels that these three corporate strategic initiatives best
deliver short, medium and long term shareholder value through accelerated
revenue growth and investment in state of the art intellectual property
assets.

    Theralase Technologies Inc. designs, develops and manufactures patented,
super-pulsed laser technology used in a wide range of bio-stimulation and
bio-destruction clinical applications. The Theralase technology platform
targets several diverse healthcare sectors -- firstly, for non-invasive pain
management and clinical therapy, in hundreds of neural muscular skeletal
conditions, including arthritis -- secondly, to bio-stimulate and accelerate
wound care and healing, including; bone fracture regeneration and
osteoarthritic conditions -- and thirdly, combining photodynamic compounds
with super-pulsed, biofeedback laser technology to attack specifically
targeted cancers, bacterium, viruses and fat cells.
    For a complete profile of Theralase Technologies Inc. and its products
visit the corporate website, www.theralase.com and the regulatory website at
www.sedar.com.

    This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of the contents of this
    release.





For further information:

For further information: Roger Dumoulin-White, President & CEO, Phone:
(416) 447-8455, e-mail: rwhite@theralase.com

Organization Profile

THERALASE TECHNOLOGIES INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890